Centogene
↗Rostock, Germany
Centogene is a commercial-stage life sciences company that specializes in rare and neurodegenerative diseases. It transforms real-world clinical, genetic, and multiomic data into actionable insights for patients, physicians, and pharmaceutical partners. The company operates a massive Biodatabank featuring over 1 million patients from over 120 countries, with a significant emphasis on populations of non-European descent.
In early 2025, the company's operating business (Centogene GmbH) was acquired by Charme Capital Partners, a pan-European private equity firm. The company now focuses on providing diagnostic services, multiomic testing, and clinical trial support while leveraging its proprietary AI-driven bioinformatics platform to accelerate drug discovery for external pharmaceutical partners.
CLASSIFICATION
Company Type:Diagnostics
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Diagnostics & Rare Disease Data
SIZE & FINANCIALS
Employees:201-500
Revenue:$50M-$100M
Founded:2006
Ownership:private
Status:acquired
FUNDING
Stage:Acquired
Total Raised:$28M
Investors:Charme Capital Partners, TVM Capital, Credit Mutuel Equity, Deutsche Private Equity, Careventures, Qatar Investment Authority
STOCK
Exchange:OTC
Ticker:CNTGF
Market Cap:$9.4M
PIPELINE
Stage:Preclinical
Lead Drug Stage:Preclinical
Modalities:Diagnostics, Small molecule, Multiomics, Bioinformatics
Active Trials:5
Trial Phases:-
FDA Approvals:1
EMA Approvals:1
CORPORATE STRUCTURE
Parent Company:Charme Capital Partners
Acquired By:Charme Capital Partners (2025-03-01)
Subsidiaries:Centogene US LLC, Centogene India Private Limited, Centogene Brazil
Key Partnerships:Pfizer (Data access and rare disease target discovery), Evotec (Drug discovery for Gaucher disease), Denali Therapeutics (ROPAD study for Parkinson's), Takeda (Genetic testing access for LSD patients), Twist Bioscience (NGS target enrichment panels), Lifera (Joint venture in Saudi Arabia for omics services)
COMPETITION
Position:Niche Player
Competitors:Invitae, Fulgent Genetics, Myriad Genetics, 23andMe, Illumina
LEADERSHIP
Key Executives:
David Jiménez - CEO
Francisco de Borja Valor Martínez - CFO
Prof. Peter Bauer - Chief Medical and Genomic Officer
Scientific Founders:Arndt Rolfs
Board Members:Peer Schatz (Chairman), Mary Sheahan
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Centogene. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.